{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:35:56Z","timestamp":1791430556504,"version":"4.3.3"},"reference-count":75,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.transci.2026.104483","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T06:55:06Z","timestamp":1782543306000},"page":"104483","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Lipoprotein apheresis: From familial hypercholesterolemia and elevated lipoprotein(a) to emerging roles in peripheral arterial and renal disease"],"prefix":"10.1016","volume":"65","author":[{"given":"Menatalla","family":"Nadim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamac","family":"Akgun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transci.2026.104483_bib1","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/clinchem\/hvaa247","article-title":"Lipoprotein(a) and cardiovascular disease","volume":"67","author":"Kamstrup","year":"2021","journal-title":"Clin Chem"},{"key":"10.1016\/j.transci.2026.104483_bib2","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.transci.2026.104483_bib3","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) concentrations and incident atherosclerotic cardiovascular disease","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.transci.2026.104483_bib4","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/j.jacl.2022.08.007","article-title":"Use of lipoprotein(a) in clinical practice: a biomarker whose time has come","volume":"16","author":"Wilson","year":"2022","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.transci.2026.104483_bib5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11883-019-0787-5","article-title":"Current role of lipoprotein apheresis","volume":"21","author":"Thompson","year":"2019","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.transci.2026.104483_bib6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11883-021-00911-w","article-title":"LDL apheresis and Lp(a) apheresis: a clinician\u2019s perspective","volume":"23","author":"Kay\u0131k\u00e7\u0131o\u011flu","year":"2021","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.transci.2026.104483_bib7","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/01.ATV.4.3.276","article-title":"Specific sorbent of apolipoprotein B-containing lipoproteins for plasmapheresis","volume":"4","author":"Yokoyama","year":"1984","journal-title":"Arteriosclerosis"},{"key":"10.1016\/j.transci.2026.104483_bib8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0021-9150(87)90089-X","article-title":"A new low density lipoprotein apheresis system using two dextran sulfate cellulose columns","volume":"68","author":"Mabuchi","year":"1987","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.transci.2026.104483_bib9","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/eurheartj\/ehad197","article-title":"2023 update on European Atherosclerosis Society consensus statement on homozygous familial hypercholesterolaemia","volume":"44","author":"Cuchel","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.transci.2026.104483_bib10","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(21)02001-8","article-title":"Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study","volume":"399","author":"Tromp","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.transci.2026.104483_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2024.118601","article-title":"The German Lipoprotein Apheresis Registry, summary of the eleventh annual report","volume":"398","author":"Schettler","year":"2024","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.transci.2026.104483_bib12","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1016\/j.jacl.2024.03.001","article-title":"A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice","volume":"18","author":"Koschinsky","year":"2024","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.transci.2026.104483_bib13","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1001\/jamacardio.2022.0987","article-title":"Lipoprotein(a) and its significance in cardiovascular disease: a review","volume":"7","author":"Lau","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.transci.2026.104483_bib14","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jacl.2017.04.114","article-title":"Toward an international consensus, integrating lipoprotein apheresis and new lipid-lowering drugs","volume":"11","author":"Stefanutti","year":"2017","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.transci.2026.104483_bib15","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/MOL.0000000000000853","article-title":"New algorithms for treating homozygous familial hypercholesterolemia","volume":"33","author":"Tromp","year":"2022","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.transci.2026.104483_bib16","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.3390\/jcm9072103","article-title":"Lipoprotein(a) lowering, from lipoprotein apheresis to antisense oligonucleotide approach","volume":"9","author":"Greco","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.transci.2026.104483_bib17","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3390\/pharmaceutics15020323","article-title":"Inclisiran, safety and effectiveness of small interfering RNA in inhibition of PCSK-9","volume":"15","author":"Wo\u0142owiec","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.transci.2026.104483_bib18","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.032031","article-title":"Harnessing RNA interference for cholesterol lowering: the bench-to-bedside story of inclisiran","volume":"13","author":"Wilkinson","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.transci.2026.104483_bib19","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/MOL.0000000000000999","article-title":"Peripheral arterial disease associated with elevated lipoprotein(a): a review of the evidence and treatment approaches","volume":"36","author":"Bhatia","year":"2025","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.transci.2026.104483_bib20","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.3390\/jcm13041121","article-title":"Heparin-mediated extracorporeal low-density lipoprotein precipitation apheresis for treating peripheral arterial disease in patients with chronic kidney disease","volume":"13","author":"Rotella","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.transci.2026.104483_bib21","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1053\/j.ajkd.2003.08.012","article-title":"A combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children","volume":"42","author":"Hattori","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.transci.2026.104483_bib22","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1681\/ASN.20233411S1980b","article-title":"Low-density lipoprotein (LDL) apheresis removes atherogenic mediators in focal segmental glomerulosclerosis","volume":"34","author":"Humphrey","year":"2023","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.transci.2026.104483_bib23","doi-asserted-by":"crossref","first-page":"S166","DOI":"10.1016\/j.ekir.2019.05.429","article-title":"Liposorber\u00ae LA-15 system for LDL apheresis in drug resistant primary focal segmental glomerulosclerosis patients: interim results","volume":"4","author":"Krishnappa","year":"2019","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.transci.2026.104483_bib24","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/trf.70083","article-title":"Beyond lipids: systemic effects of lipoprotein apheresis","volume":"66","author":"Nadim","year":"2026","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2026.104483_bib25","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.transci.2026.104483_bib26","doi-asserted-by":"crossref","first-page":"6311","DOI":"10.3390\/jcm13216311","article-title":"Role of lipoprotein(a) reduction in cardiovascular disease","volume":"13","author":"Schuth","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.transci.2026.104483_bib27","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.033654","article-title":"Genetics and pathophysiological mechanisms of lipoprotein(a)-associated cardiovascular risk","volume":"13","author":"Volgman","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.transci.2026.104483_bib28","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2019.10.019","article-title":"Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes","volume":"74","author":"Gudbjartsson","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.transci.2026.104483_bib29","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.3390\/ijms25063537","article-title":"Lipoprotein(a) and atherosclerotic cardiovascular disease: where do we stand?","volume":"25","author":"Tsioulos","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.transci.2026.104483_bib30","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3109\/10408363.2014.992063","article-title":"Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases","volume":"52","author":"Trpkovic","year":"2015","journal-title":"Crit Rev Clin Lab Sci"},{"key":"10.1016\/j.transci.2026.104483_bib31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11883-021-00951-2","article-title":"Lipoprotein(a): when to measure and how to treat?","volume":"23","author":"Rhainds","year":"2021","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.transci.2026.104483_bib32","doi-asserted-by":"crossref","first-page":"13597","DOI":"10.3390\/ijms252413597","article-title":"Reduced oxidative susceptibility of Lp(a) and LDL fractions as a pleiotropic effect of lipoprotein apheresis","volume":"25","author":"Krzesi\u0144ska","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.transci.2026.104483_bib33","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2026.104483_bib34","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s11883-023-01113-2","article-title":"Lipoprotein apheresis: current recommendations for treating familial hypercholesterolemia and elevated lipoprotein(a)","volume":"25","author":"Safarova","year":"2023","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.transci.2026.104483_bib35","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S2352-4642(24)00073-7","article-title":"Cardiovascular outcomes in patients with homozygous familial hypercholesterolaemia on lipoprotein apheresis initiated during childhood","volume":"8","author":"Reijman","year":"2024","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.transci.2026.104483_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2024.117525","article-title":"Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolaemia: an expert consensus statement from ERKNet and ESPN","volume":"392","author":"Reijman","year":"2024","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.transci.2026.104483_bib37","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jacl.2019.05.002","article-title":"A cross-national investigation of cardiovascular survival in homozygous familial hypercholesterolemia: the Sino-Roman Study","volume":"13","author":"Stefanutti","year":"2019","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.transci.2026.104483_bib38","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11883-021-00926-3","article-title":"Mighty Medic Satellite Research Group for Pediatric Dyslipidemia. Current approach to the diagnosis and treatment of heterozygote and homozygous FH children and adolescents","volume":"23","author":"Cohen","year":"2021","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.transci.2026.104483_bib39","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.atherosclerosis.2020.01.031","article-title":"Practice of lipoprotein apheresis and short-term efficacy in children with homozygous familial hypercholesterolemia: data from an international registry","volume":"299","author":"Luirink","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.transci.2026.104483_bib40","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003294","article-title":"Systematic review of low-density lipoprotein cholesterol apheresis for the treatment of familial hypercholesterolemia","volume":"5","author":"Wang","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.transci.2026.104483_bib41","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.jacasi.2023.07.011","article-title":"Clinical characteristics of homozygous familial hypercholesterolemia in Japan: a survey using a national database","volume":"3","author":"Takeji","year":"2023","journal-title":"JACC Asia"},{"key":"10.1016\/j.transci.2026.104483_bib42","doi-asserted-by":"crossref","first-page":"558","DOI":"10.5551\/jat.CR005","article-title":"Guidelines for the diagnosis and treatment of adult familial hypercholesterolemia 2022","volume":"30","author":"Harada-Shiba","year":"2023","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.transci.2026.104483_bib43","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1161\/ATVBAHA.123.320609","article-title":"Evinacumab and cardiovascular outcome in patients with homozygous familial hypercholesterolemia","volume":"44","author":"B\u00e9liard","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.transci.2026.104483_bib44","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/eurjpc\/zwae144","article-title":"Current treatments for the management of homozygous familial hypercholesterolemia: a systematic review and commentary","volume":"31","author":"Gu","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.transci.2026.104483_bib45","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1038\/s41591-023-02494-2","article-title":"RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts","volume":"29","author":"Watts","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.transci.2026.104483_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2023.117305","article-title":"Long-term outcomes of liver transplantation for homozygous familial hypercholesterolaemia in Australia and New Zealand","volume":"387","author":"Page","year":"2023","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.transci.2026.104483_bib47","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.transci.2026.104483_bib48","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.atherosclerosis.2016.10.017","article-title":"HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom","volume":"255","author":"France","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.transci.2026.104483_bib49","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0021-9150(99)00398-6","article-title":"Prospective randomised cross-over comparison of three LDL-apheresis systems in statin pretreated patients with familial hypercholesterolaemia","volume":"151","author":"Schmaldienst","year":"2000","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.transci.2026.104483_bib50","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0021-9150(93)90068-6","article-title":"Reduction of lipoprotein(a) by LDL-apheresis using a dextran sulfate cellulose column in patients with familial hypercholesterolemia","volume":"100","author":"Koizumi","year":"1993","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.transci.2026.104483_bib51","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3390\/ijms19010094","article-title":"Lowering low-density lipoprotein particles in plasma using dextran sulphate co-precipitates procoagulant extracellular vesicles","volume":"19","author":"Wang","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.transci.2026.104483_bib52","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2796.1993.tb00781.x","article-title":"Different effects of two methods of low-density lipoprotein apheresis on the coagulation and fibrinolytic systems","volume":"234","author":"Knisel","year":"1993","journal-title":"J Intern Med"},{"key":"10.1016\/j.transci.2026.104483_bib53","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00041433-199202000-00009","article-title":"Recent developments in low-density lipoprotein apheresis","volume":"3","author":"Demant","year":"1992","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.transci.2026.104483_bib54","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.atherosclerosis.2018.01.005","article-title":"High serum triglyceride concentrations in patients with homozygous familial hypercholesterolemia attenuate the efficacy of lipoprotein apheresis by dextran sulfate adsorption","volume":"270","author":"Drouin-Chartier","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.transci.2026.104483_bib55","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1093\/ndt\/gfn127","article-title":"Protein adsorption during LDL-apheresis: proteomic analysis","volume":"23","author":"Dihazi","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transci.2026.104483_bib56","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.jacl.2013.03.002","article-title":"Emerging low-density lipoprotein (LDL) therapies: management of severely elevated LDL cholesterol, the role of LDL-apheresis","volume":"7","author":"McGowan","year":"2013","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.transci.2026.104483_bib57","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1053\/meta.2000.9505","article-title":"Lipid reductions by low-density lipoprotein apheresis: a comparison of three systems","volume":"49","author":"Jovin","year":"2000","journal-title":"Metabolism"},{"key":"10.1016\/j.transci.2026.104483_bib58","doi-asserted-by":"crossref","DOI":"10.1097\/MOL.0000000000000998","article-title":"Lipoprotein(a) and peripheral artery disease: contemporary evidence and therapeutic advances","volume":"36","author":"Thanigaimani","year":"2025","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.transci.2026.104483_bib59","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1111\/1744-9987.14046","article-title":"Current status of low-density lipoprotein apheresis treatment for patients with peripheral artery disease and chronic kidney disease in Japanese clinical database","volume":"27","author":"Watanabe","year":"2023","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.transci.2026.104483_bib60","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1093\/ndt\/gfp342","article-title":"Low-density lipoprotein apheresis for haemodialysis patients with peripheral arterial disease reduces reactive oxygen species production","volume":"24","author":"Hara","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transci.2026.104483_bib61","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1093\/eurheartj\/ehy862","article-title":"Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong LDL-C reduction by PCSK9 antibody treatment","volume":"40","author":"Stiekema","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.transci.2026.104483_bib62","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.atherosclerosis.2022.10.002","article-title":"Lipoprotein(a) and long-term outcome in patients with peripheral artery disease undergoing revascularization","volume":"363","author":"Zierfuss","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.transci.2026.104483_bib63","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrneph.2017.155","article-title":"Dyslipidaemia in nephrotic syndrome: mechanisms and treatment","volume":"14","author":"Agrawal","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.transci.2026.104483_bib64","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/1744-9987.14056","article-title":"Updated evidence of beneficial effect of LDL apheresis for refractory nephrotic syndrome due to a variety of causative diseases for nationwide and global approval","volume":"27","author":"Muso","year":"2023","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.transci.2026.104483_bib65","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/1744-9987.13694","article-title":"Favorable therapeutic efficacy of low-density lipoprotein apheresis for nephrotic syndrome with impaired renal function","volume":"26","author":"Muso","year":"2022","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.transci.2026.104483_bib66","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1681\/ASN.2004080629","article-title":"Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating the phosphatidylinositol 3-kinase\/AKT-signaling pathway","volume":"16","author":"Bussolati","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.transci.2026.104483_bib67","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/s12933-023-02025-w","article-title":"Klotho inhibits renal ox-LDL deposition via IGF-1R\/RAC1\/OLR1 signaling to ameliorate podocyte injury in diabetic kidney disease","volume":"22","author":"Jiang","year":"2023","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"10.1016\/j.transci.2026.104483_bib68","article-title":"Study of 15 cases of cholesterol crystal embolism with low-density lipoprotein apheresis","volume":"35","author":"Shimizu","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transci.2026.104483_bib69","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1177\/2047487319833504","article-title":"PCSK9 monoclonal antibodies and lipoprotein apheresis for lowering lipoprotein(a): making choices in an era of RNA-based therapies","volume":"26","author":"Ruscica","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.transci.2026.104483_bib70","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2337\/dc18-1491","article-title":"Inclisiran lowers LDL-C and PCSK9 irrespective of diabetes status: the ORION-1 randomized clinical trial","volume":"42","author":"Leiter","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.transci.2026.104483_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154221","article-title":"PCSK9 inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a)","volume":"107","author":"Watts","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.transci.2026.104483_bib72","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1161\/CIRCRESAHA.115.306471","article-title":"From lipids to inflammation: new approaches to reducing atherosclerotic risk","volume":"118","author":"Shapiro","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.transci.2026.104483_bib73","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.transci.2026.104483_bib74","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41569-023-00892-0","article-title":"International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia","volume":"20","author":"Watts","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.transci.2026.104483_bib75","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/eurjpc\/zwae032","article-title":"Lipoprotein(a) and cardiovascular disease: sifting the evidence to guide future research","volume":"31","author":"Kamstrup","year":"2024","journal-title":"Eur J Prev Cardiol"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050226001151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050226001151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T19:31:13Z","timestamp":1785439873000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050226001151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":75,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1473050226001151"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2026.104483","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipoprotein apheresis: From familial hypercholesterolemia and elevated lipoprotein(a) to emerging roles in peripheral arterial and renal disease","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2026.104483","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104483"}}